Association of Ki-67 Expression and Response Neoadjuvant Chemotherapy on Invasive Breast Cancer Patient in Bandung

Andri Rezano, Chen En Pan, Afrida Aizzatun Istiqomah, Almira Zada


Objective: To compare the size of tumour before and after neoadjuvant chemotherapy between three Ki-67 expression categories and also to find out the predictive value of Ki-67 towards neoadjuvant chemotherapy outcome.  

Methods: This study was a retrospective study by obtaining data from the 2015’s cohort of invasive breast cancer patient medical record from Dr. Hasan Sadikin General Hospital. Only female patient with Ki-67 expression level recorded and data from pre and post neoadjuvant chemotherapy were taken. Changes of the tumor size in terms of mm3were compared. The data obtained was analyzed using One-way ANOVA. A total of 25 patients were included in this study. The p value for the changes in mm3was p<0.05. 

Results: The study showed significant difference in changes of tumour size for Ki-67 level >20% compared to <14% (p=0.011) and 14-20% (p=0.018). Based on the result, neoadjuvant chemotherapy is proven to have similar effects on patient with Ki-67 expression of <14 and 14 - 20 but less effective on patient with Ki-67 expression of >20. 

Conclusions: The effect of neoadjuvant chemotherapy is dependent to Ki-67 expression and also showing potential as a predictive marker for neoadjuvant chemotherapy response


Breast cancer, Ki-67, neoadjuvant chemotherapy, invasive breast cancer, tumour.


Siegel R, Naishadham D, Jemal A. Cancer statistics. CA Cancer J. Clin. 2012; 62(1):10-29.

World Health Organization. Cancer country profiles 2013. [cited 2016 Apr 1]. Available from:

Lotsch J, Sipila R, Tasmuth T, Kringel D, Estlander AM, Meretoja T, et al. Machine-learning-derived classifier predicts absence of persistent pain after breast cancer surgery with high accuracy. Breast Cancer Res Treat. 2018; 72, 3515–3524.

Burcombe RJ, Makris A, Richman PI, Daley FM, Noble S, Pittam M, Wright D, et al. Evaluation of ER, PgR, HER-2 and Ki-67 as predictors of response to neoadjuvant anthracycline chemotherapy for operable breast cancer. Br J Cancer. 2005; 92(1):147–155.

Ingolf JB, Russalina M, Simona M, Julia R, Gilda S, Bohle RM, et al. Can ki-67 play a role in prediction of breast cancer patients’ response to neoadjuvant chemotherapy? Biomed Res Int. 2014;2014:1-7.

Inwald EC, Klinkhammer-Schalke M, Hofstädter F, Zeman F, Koller M, Gerstenhauer M, et al. Ki-67 is a prognostic parameter in breast cancer patients: results of a large population-based cohort of a cancer registry. Breast Cancer Res Treat. 2013;139(2):539–52.

Kim KI, Lee KH, Kim TR, Chun YS, Lee TH, Park HK. Ki-67 as a Predictor of Response to Neoadjuvant Chemotherapy in Breast Cancer Patients. J Breast Cancer. 2014;17(1):40.

Fasching PA, Heusinger K, Haeberle L, Niklos M, Hein A, Bayer CM, et al. Ki67, chemotherapy response, and prognosis in breast cancer patients receiving neoadjuvant treatment. BMC Cancer. 2011;11(1):486.

Gnant M, Thomssen C, Harbeck N. St. Gallen/Vienna 2015: A Brief Summary of the Consensus Discussion. Breast Care (Basel). 2015;10(2):124–30.

Tashima R, Nishimura R, Osako T, Nishiyama Y, Okumura Y, Nakano M, et al. Evaluation of an Optimal Cut-Off Point for the Ki-67 Index as a Prognostic Factor in Primary Breast Cancer: A Retrospective Study. PLoS One. 2015;10(7):e0119565.


  • There are currently no refbacks.

This journal indexed by:



Creative Commons License
IJIHS is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License

View My Stats